Lupin launches Betamethasone Dipropionate Ointment USP
Pharma major Lupin Limited announced on Friday about the launch of its Betamethasone Dipropionate ointment USP (augmented), 0.05 per cent, having received an approval from United States Food & Drug Administration (USFDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit 3) facility in India.
Betamethasone Dipropionate ointment USP, 0.05 per cent, is the generic equivalent of Diprolene ointment, 0.05 per cent by Merck Sharp and Dohme Corp. The drug is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients of 13 years and above. The ointment had annual sales of approximately US$ 21 million in the US (IQVIA MAT January, 2020)
Lupin is an innovation-led transnational pharmaceutical company, headquartered in Mumbai (India). The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs for various markets.
On Friday, the stock closed at Rs 641.60, up by 1.19 per cent or Rs 7.55 per share. The 52-week high is recorded at Rs 882.15 and the 52-week low is Rs 505 on BSE.